Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CEO Sells $20,681.20 in Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $6.94, for a total transaction of $20,681.20. Following the completion of the sale, the chief executive officer now owns 762,419 shares of the company’s stock, valued at $5,291,187.86. This trade represents a 0.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The stock was sold at an average price of $6.29, for a total value of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total value of $20,364.24.

Cryoport Stock Performance

Shares of Cryoport stock opened at $6.09 on Friday. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11. The firm’s 50-day moving average is $6.68 and its 200 day moving average is $7.32. The stock has a market cap of $303.95 million, a price-to-earnings ratio of -1.80 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the prior year, the company posted ($0.29) EPS. Sell-side analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Finally, UBS Group upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.67.

Institutional Trading of Cryoport

Several institutional investors have recently added to or reduced their stakes in the business. PharVision Advisers LLC bought a new position in shares of Cryoport during the fourth quarter valued at $259,000. Squarepoint Ops LLC lifted its stake in Cryoport by 208.4% during the 4th quarter. Squarepoint Ops LLC now owns 36,499 shares of the company’s stock valued at $284,000 after acquiring an additional 24,665 shares during the period. State of Wyoming boosted its holdings in shares of Cryoport by 170.2% during the 4th quarter. State of Wyoming now owns 32,426 shares of the company’s stock valued at $252,000 after acquiring an additional 20,427 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Cryoport in the fourth quarter worth approximately $116,000. Finally, Silvercrest Asset Management Group LLC raised its holdings in shares of Cryoport by 77.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company’s stock valued at $5,780,000 after purchasing an additional 323,216 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.